Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
267.47
-15.68 (-5.54%)
At close: Jul 17, 2026, 4:00 PM EDT
269.00
+1.53 (0.57%)
After-hours: Jul 17, 2026, 4:50 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $435.33. The average 1-year stock price forecast is 62.76% higher than the current stock price, while the lowest is $310 (+15.90%) and the highest is $550 (+105.63%).
Price Target: $435.33 (+62.76%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 14 | 14 | 15 | 14 | 14 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 7 | 8 | 8 | 8 | 8 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 28 | 30 | 29 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $380 | Buy | Maintains | $380 | +42.07% | Jul 16, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $444 | Buy | Maintains | $444 | +66.00% | Jul 14, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $460 → $410 | Buy | Reiterates | $460 → $410 | +53.29% | Jul 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $470 → $485 | Buy | Reiterates | $470 → $485 | +81.33% | Jul 13, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $370 → $400 | Hold | Maintains | $370 → $400 | +49.55% | Jul 10, 2026 |
Financial Forecast
Revenue This Year
5.60B
from 3.71B
Increased by 50.88%
Revenue Next Year
7.27B
from 5.60B
Increased by 29.69%
EPS This Year
9.37
from 5.08
Increased by 84.51%
EPS Next Year
13.47
from 9.37
Increased by 43.75%
EPS and Forward PE are based on non-GAAP adjusted numbers.